| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23068 |
| Drug | Linzagolix |
| Brand | Yselty® |
| Indication | Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
| Assessment Process | |
| Rapid review commissioned | 09/11/2023 |
| Rapid review completed | 19/12/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of linzagolix compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2024 |
| Pre-submission consultation with Applicant | 16/04/2024 |
